Abiomed specializes in advanced cardiac technologies, primarily focusing on the Impella® heart pumps, which are designed to provide hemodynamic support for patients with severe coronary artery disease and advanced heart failure. The Impella devices, including models like the Impella CP® and Impella 5.5®, are minimally invasive, catheter-based pumps that assist the heart's pumping function during critical procedures such as high-risk percutaneous coronary interventions (PCI) and in cases of cardiogenic shock. These heart pumps utilize SmartAssist® technology, which offers real-time intelligence to optimize therapy and improve patient outcomes, making them a vital tool in modern cardiac care.

In addition to the Impella heart pumps, Abiomed has developed the Breethe OXY-1 System™, a compact cardiopulmonary support system that integrates an oxygen concentrator to enhance patient mobility while providing essential respiratory support. The company is committed to ongoing clinical research, having invested significantly in studies that validate the safety and efficacy of its technologies. With a focus on innovation, Abiomed aims to create smaller, smarter, and more connected devices that enhance patient care and recovery, while also providing comprehensive clinical support to healthcare professionals.

United States

Based in Danvers, Massachusetts, USA, Abiomed, Inc., part of Johnson & Johnson MedTech, is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit www.abiomed.com.

Important Safety Info: https://bit.ly/39kvb47

Abiomed

Company Details